Riquent is the first ever drug entrant exclusively developed for the treatment of lupus renal ailments in more than 30 years now. Lupus is the unrelieved, life threatening auto-immune ailment bothering to nearly one million people in the United States and European Union. Almost 90 percent of the lupus patients are found to be from the female gender. Majority of these patients have been reported of developing lupus ailment during their childhood phase only, and roughly 50 percent of the lupus patients are suffering from the renal ailments.

Renal disease is one of the most serious features of lupus and may result in typical irretrievable or permanent kidney damage, kidney failure as well as may require to be put on dialysis too. Antibodies to dsDNA could be tracked in nearly all lupus patients and are considered diagnostic for the ailment. The present regular treatment for lupus renal ailment frequently incorporates treating with higher dosage of corticosteroids and immuno suppressive medications that may end up in serious types of the side effects such as diabetes, hypertension and sterility, and also it may render the patient posed to opportunistic infections. Moreover, the death toll from the present treatment could be even higher than the ailment itself.       

Riquent is designed to be well especial and not suppressing the usual healthy functions of the immune system. The drug is proved to be well resisted during all the studies, and it never exhibited any evident alterations in the general occurrence of serious adverse affects between the patients treated with Riquent and patients treated with placebo.